Monday, November 18, 2024
Author
TGV-inhalonix's New Study Shows Promise To Fight Deadly CF Lung Infections
Fri, Jun 9, 2017 11:20 ET
New York-based company says its drug candidate demonstrates breakthrough results against pathogens that cause lethal infections in cystic fibrosis patients
TGV-inhalonix's New Drug To Help Patients With Resistant Fungal Lung Infections
Thu, May 11, 2017 13:55 ET
The New York drug development company says its Mul-1867 drug candidate shows high potential for treating cystic fibrosis and other severe lung infections.
